Discover

EXOZ
eXoZymes, Inc.
4.09
1 x 6.10
1 x 7.60
bid
ask
+
0.09
2.25%
1 @ 05:15 PM
4.12 +0.03 (0.66%)
Ytd-62.48%
1y-67.54%
4.02
day range
4.96
4.00
52 week range
16.50
Open4.08Prev Close4.00Low4.02High4.96Mkt Cap38.06M
Vol32.09KAvg Vol7.25KEPS-1.19P/EN/AForward P/EN/A
Beta3.19Short RatioN/AInst. OwnN/ADividendN/ADiv YieldN/A
Ex Div DateN/AEarning05-1250-d Avg6.09200-d Avg8.111yr Est0.00

EXOZ News

Water Tower Research Publishes Initiation of Coverage Report on eXoZymes, Inc., "Converting Cell-Free Science into a Scalable and Repeatable Commercial Opportunity"
thenewswire.com
Water Tower Research Publishes Initiation of Coverage Report on eXoZymes, Inc., "Converting Cell-Fre

October 2, 2026, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has publishe

Head to Head Contrast: Iovance Biotherapeutics (NASDAQ:IOVA) vs. eXoZymes (NASDAQ:EXOZ)
defenseworld.net
Head to Head Contrast: Iovance Biotherapeutics (NASDAQ:IOVA) vs. eXoZymes (NASDAQ:EXOZ)

Iovance Biotherapeutics (NASDAQ: IOVA - Get Free Report) and eXoZymes (NASDAQ: EXOZ - Get Free Repor

12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session

Gainers EXoZymes (NASDAQ:EXOZ) stock increased by 7.5% to $7.18 during Wednesday's after-market

eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT
accessnewswire.com
eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT

Program expected to commence in Q4 2026 and establish a roadmap for larger-scale production in 2027

eXoZymes Q2 Earnings Call Highlights
defenseworld.net
eXoZymes Q2 Earnings Call Highlights

eXoZymes (NASDAQ: EXOZ) outlined progress toward commercializing its NCT program, including a report

eXoZymes Q2 Earnings Call Highlights
marketbeat.com
eXoZymes Q2 Earnings Call Highlights

eXoZymes NASDAQ: EXOZ outlined progress toward commercializing its NCT program, including a reported

12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session

Gainers Werewolf Therapeutics (NASDAQ:HOWL) stock moved upwards by 77.1% to $0.76 during Thursday&#

eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today
accessnewswire.com
eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today

Management to host Q2 2026 update at 5PM ET / 2PM PT, today. LOS ANGELES, CA / ACCESS Newswire / Aug

eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets
accessnewswire.com
eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-s

Optimized process delivered a 10-fold improvement in productivity, significantly improving the estim

eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026
accessnewswire.com
eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform ab

eXoZymes (NASDAQ:EXOZ)  Shares Down 1.1%   – What’s Next?
defenseworld.net
eXoZymes (NASDAQ:EXOZ) Shares Down 1.1% – What’s Next?

eXoZymes Inc. (NASDAQ: EXOZ - Get Free Report)'s stock price dropped 1.1% on Monday. The stock trade

eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing
accessnewswire.com
eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Bioman

Company to collaborate with Lawrence Berkeley National Laboratory on AI-enabled digital twins design

eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery
accessnewswire.com
eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery

Award allows eXoZymes to expand its portfolio of proprietary new-to-nature molecules and potential f

eXoZymes Inc. Announces Closing of $6 Million Public Offering
accessnewswire.com
eXoZymes Inc. Announces Closing of $6 Million Public Offering

LOS ANGELES, CA / ACCESS Newswire / June 17, 2026 / eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes" or "Comp

eXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrants
accessnewswire.com
eXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrants

LOS ANGELES, CA / ACCESS Newswire / June 8, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes" or

eXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) Program
accessnewswire.com
eXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) Program

LOS ANGELES, CA / ACCESS Newswire / May 7, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") -

eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast
accessnewswire.com
eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanuf

LOS ANGELES, CA / ACCESS Newswire / April 10, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes")

eXoZymes Provides Fourth Quarter and Full Year 2025 Update
accessnewswire.com
eXoZymes Provides Fourth Quarter and Full Year 2025 Update

Management to Host Conference Call Today at 5:30 PM Eastern LOS ANGELES, CA / ACCESS Newswire / Marc

Earnings Scheduled For March 31, 2026
benzinga.com
Earnings Scheduled For March 31, 2026

eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026
accessnewswire.com
eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026

LOS ANGELES, CA / ACCESS Newswire / March 25, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes")

Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability
accessnewswire.com
Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability

LOS ANGELES, CA / ACCESS Newswire / March 18, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes")

eXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium
accessnewswire.com
eXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium

LOS ANGELES, CA / ACCESS Newswire / March 12, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes")

Head-To-Head Analysis: eXoZymes (NASDAQ:EXOZ) & Curis (NASDAQ:CRIS)
defenseworld.net
Head-To-Head Analysis: eXoZymes (NASDAQ:EXOZ) & Curis (NASDAQ:CRIS)

eXoZymes (NASDAQ: EXOZ - Get Free Report) and Curis (NASDAQ: CRIS - Get Free Report) are both small-

Earnings Scheduled For November 13, 2025
benzinga.com
Earnings Scheduled For November 13, 2025

benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session

benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session

benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session

benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session

benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session

benzinga.com
Earnings Scheduled For April 2, 2025

benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session